640 related articles for article (PubMed ID: 12659404)
1. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
Freeman EW
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
Freeman EW; Kroll R; Rapkin A; Pearlstein T; Brown C; Parsey K; Zhang P; Patel H; Foegh M;
J Womens Health Gend Based Med; 2001; 10(6):561-9. PubMed ID: 11559453
[TBL] [Abstract][Full Text] [Related]
3. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
Cianci A; De Leo V
Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
[TBL] [Abstract][Full Text] [Related]
4. Yasmin: the reason why.
Thorneycroft IH
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():13-8; discussion 42-3. PubMed ID: 12659402
[TBL] [Abstract][Full Text] [Related]
5. Experiences with Yasmin: the acceptability of a novel oral contraceptive and its effect on well-being.
Mansour D
Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():35-41; discussion 42-3. PubMed ID: 12659405
[TBL] [Abstract][Full Text] [Related]
6. Effect of an oral contraceptive containing drospirenone and ethinylestradiol on general well-being and fluid-related symptoms.
Apter D; Borsos A; Baumgärtner W; Melis GB; Vexiau-Robert D; Colligs-Hakert A; Palmer M; Kelly S
Eur J Contracept Reprod Health Care; 2003 Mar; 8(1):37-51. PubMed ID: 12725674
[TBL] [Abstract][Full Text] [Related]
7. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
Pearlstein TB; Bachmann GA; Zacur HA; Yonkers KA
Contraception; 2005 Dec; 72(6):414-21. PubMed ID: 16307962
[TBL] [Abstract][Full Text] [Related]
8. The acceptability of a novel oral contraceptive containing drospirenone and its effect on well-being.
Boschitsch E; Skarabis H; Wuttke W; Heithecker R
Eur J Contracept Reprod Health Care; 2000 Dec; 5 Suppl 3():34-40. PubMed ID: 11246600
[TBL] [Abstract][Full Text] [Related]
9. Premenstrual dysphoric disorder symptom cluster improvement by cycle with the combined oral contraceptive ethinylestradiol 20 mcg plus drospirenone 3 mg administered in a 24/4 regimen.
Marr J; Niknian M; Shulman LP; Lynen R
Contraception; 2011 Jul; 84(1):81-6. PubMed ID: 21664515
[TBL] [Abstract][Full Text] [Related]
10. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
van Vloten WA; van Haselen CW; van Zuuren EJ; Gerlinger C; Heithecker R
Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
[TBL] [Abstract][Full Text] [Related]
11. Added benefits of drospirenone for compliance.
Foidart JM
Climacteric; 2005 Oct; 8 Suppl 3():28-34. PubMed ID: 16203653
[TBL] [Abstract][Full Text] [Related]
12. [The efficiency of oral contraception containing drospirenone in treating symptoms of premenstrual syndrome or premenstrual dysphoric disorder in gyneacology practice].
Svojanovská K
Ceska Gynekol; 2010 Oct; 75(5):474-80. PubMed ID: 21374928
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
Sangthawan M; Taneepanichskul S
Contraception; 2005 Jan; 71(1):1-7. PubMed ID: 15639064
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
Yonkers KA; Brown C; Pearlstein TB; Foegh M; Sampson-Landers C; Rapkin A
Obstet Gynecol; 2005 Sep; 106(3):492-501. PubMed ID: 16135578
[TBL] [Abstract][Full Text] [Related]
15. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
Yonkers KA; Pearlstein T; Fayyad R; Gillespie JA
J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
[TBL] [Abstract][Full Text] [Related]
16. Oral contraceptives and premenstrual symptoms: comparison of a 21/7 and extended regimen.
Coffee AL; Kuehl TJ; Willis S; Sulak PJ
Am J Obstet Gynecol; 2006 Nov; 195(5):1311-9. PubMed ID: 16796986
[TBL] [Abstract][Full Text] [Related]
17. A randomized study on the influence of oral contraceptives containing ethinylestradiol combined with drospirenone or desogestrel on lipid and lipoprotein metabolism over a period of 13 cycles.
Gaspard U; Endrikat J; Desager JP; Buicu C; Gerlinger C; Heithecker R
Contraception; 2004 Apr; 69(4):271-8. PubMed ID: 15033400
[TBL] [Abstract][Full Text] [Related]
18. Effect of a combination of ethinylestradiol 30 microg and drospirenone 3 mg on tolerance, cycle control, general well-being and fluid-related symptoms in women with premenstrual disorders requesting contraception.
Borges LE; Andrade RP; Aldrighi JM; Guazelli C; Yazlle ME; Isaia CF; Petracco A; Peixoto FC; Camargos AF
Contraception; 2006 Dec; 74(6):446-50. PubMed ID: 17157100
[TBL] [Abstract][Full Text] [Related]
19. Oral contraceptives containing drospirenone for premenstrual syndrome.
Lopez LM; Kaptein AA; Helmerhorst FM
Cochrane Database Syst Rev; 2012 Feb; (2):CD006586. PubMed ID: 22336820
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Yasmin in premenstrual symptoms.
Taneepanichskul S; Jaisamrarn U; Phupong V
Arch Gynecol Obstet; 2007 Jun; 275(6):433-8. PubMed ID: 17111156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
